TRIM21 is important in the early phase of inflammation in the imiquimod-induced psoriasis-like skin inflammation mouse model

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

  • Hanne Vinter
  • Ane Langkilde
  • V Ottosson, Department of Medicine, Karolinska University Hospital Solna, Stockholm, Sweden.
  • ,
  • Alexander Espinosa, Department of Medicine, Karolinska University Hospital Solna, Stockholm, Sweden.
  • ,
  • M Wahren-Herlenius, Department of Medicine, Karolinska University Hospital Solna, Stockholm, Sweden.
  • ,
  • Line Raaby
  • Claus Johansen
  • Lars Iversen

Tripartite motif-containing protein 21 (TRIM21) regulates pro-inflammatory cytokines and type I interferons and acts as an autoantigen in certain autoimmune diseases, but TRIM21 has not been investigated in psoriasis. It has been suggested that TRIM21 may have a dual function; In the early phase of inflammation, it may function as a stimulator; but upon immune stimulation, its ubiquitinating mode of action may shift from stabilization to degradation of IRF3 causing inhibition of the immune responses. The imiquimod (IMQ)-induced psoriasis-like mouse model displays features similar to those of human psoriasis. However, chronicity is lacking in this model. We investigated whether the role of TRIM21 in psoriasis was pro-inflammatory or anti-inflammatory. We hypothesized that a shift of the TRIM21-ubiquitinating mode of action may explain the lack of chronicity in the IMQ-induced psoriasis-like mouse model. We showed that TRIM21 expression is increased in lesional psoriatic skin and in the early phase of IMQ-induced inflammation both in vitro and in vivo. Surprisingly, inflammation was significantly less pronounced in TRIM21 knockout (KO) mice than in WT mice as shown by ear thickness measured at day 8, 9 and 10 after treatment start, by spleen weight as a marker of systemic effect of IMQ at 10 days after treatment start and by expression of IL-12p40 at day 3 and 10 after treatment start and IL-17A at day 3 after treatment start. Therefore, induction of TRIM21 expression cannot explain the lack of chronicity in the IMQ-induced psoriasis-like skin inflammation mouse model. This article is protected by copyright. All rights reserved.

Original languageEnglish
Article number26(8)
JournalExperimental Dermatology
Pages (from-to)713-720
ISSN0906-6705
DOIs
Publication statusPublished - Aug 2017

See relations at Aarhus University Citationformats

ID: 108908795